Navigation Links
Private equity companies purchase nursing homes, but care does not suffer
Date:9/9/2008

rn led to increased attention and Congressional hearings on the topic.

"We wanted to study this issue in a quantitatively rigorous way, for example controlling for broader trends within nursing home markets and particular facilities over time," says Grabowski. "The attention to these transactions and the issues they raise is important, and we hoped our study would provide a comprehensive and accurate view of what was happening."

Stevenson and Grabowski examined a range of nursing home outcomes and compared the quality of care in private equity purchased nursing homes to those that had not undergone these transactions.

The researchers looked at various indicators including nurse and aide staffing, survey deficiencies, and a range of resident outcomes including the prevalence of catheter use, urinary tract infections, weight loss, restraint use, pressure ulcers, residents' ability to take care of their own daily needs, and range of motion loss.

When the data were analyzed, the researchers found scant evidence to suggest that the overall quality of resident care had declined substantially following these purchases. Some factors, such as RN staffing, did in fact decline. But others, such as aide staffing, catheter use, UTIs, weight loss, and pressure ulcers, actually improved.

"After taking facility and market trends into account, we did not find a substantial drop in the quality of care delivered in these nursing homes overall," says Stevenson.

The researchers caution that these findings are preliminary, given the recent nature of many of these transactions. In addition, they emphasize that it is still important to consider a range of issues around ownership transparency and accountability that extend beyond private equity investment.

"Our study provides an initial snapshot that is somewhat reassuring," says Stevenson. "But the attention on these deals and the corporate structures that emerge from th
'/>"/>

Contact: David Cameron
david_cameron@hms.harvard.edu
617-432-0441
Harvard Medical School
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related medicine news :

1. Vickie Milazzo Institute Makes Inc.s List of Top 5000 Fastest-Growing Private Companies in America
2. Z Trim Holdings, Inc. Announces Private Placement Funding
3. Jackson Healthcare Ranked 48th of All Health Companies on Inc. Magazine's 2008 List of 5000 Fastest Growing Private Companies
4. invivodata Recognized as One of Pittsburghs Fastest Growing Private Companies
5. The Coding Source Named to Inc. Magazines 27th Annual List of Americas 500 Fastest-Growing Private Companies
6. Vigilan Recognized as One of the Fastest-Growing Private Companies in the U.S.
7. VirtualHealth Technologies, Inc., Announces That Its Associate, Private Access, Will Be Partnering with Genetic Alliance To Accelerate Medical Research While Protecting Privacy
8. VirtualHealth Technologies, Inc., Announces Its Associate, Private Access, Appoints Marc Kirshbaum as President & COO
9. Plexus Consulting Group Works With a USAID-Funded Project to Help the Private Hospitals Association of Jordan Create a Roadmap for the Future
10. Peptimmune Announces the Second Close of Series D Private Financing
11. Houston-Based Tyrell, Inc. Completes $28 Million Private Equity Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 2013 According to the National Institutes of ... epidermal necrolysis (TEN) that affects the skin and mucous membranes. ... under the age of 30 (i). In the early ... fever. As SJS advances, it affects the mucous membranes ... anus. Inflammation of the eye causes conjunctivitis (pink eye). ...
(Date:5/24/2013)... BEACH, CA (PRWEB) May 24, 2013 ... health care education community, proudly participated in festivities surrounding ... April 19-21. The event provided the perfect backdrop to ... facilities at 236 E. 3rd Street, housed in an ... Arts Building. , ACC was an active exhibitor throughout ...
(Date:5/24/2013)... FRIDAY, May 24 (HealthDay News) -- About one in ... their teens take up smoking, drinking or illicit drug ... too bad, say experts at the Substance Abuse and ... that parents are actually one of the most influential ... issues. "Surveys of teens repeatedly show that ...
(Date:5/24/2013)... May 2013, Paris, France: Routinely measuring fractional flow ... angiography for diagnosis of chest pain leads to ... four patients, according to results from a study ... routine pressure wire assessment influence management strategy at ... was designed to assess whether routine assessment of ...
(Date:5/24/2013)... youth and diabetes keeps getting worse. The latest data from ... Type 2 diabetes are at high risk to develop heart, ... than people who acquire Type 2 diabetes as adults. ... to be at very high risk for early complications when ... endocrinology in the School of Medicine at The University of ...
Breaking Medicine News(10 mins):Health News:Personal Injury Law Firm Issues New Infographic Detailing a Potential Link Between Stevens Johnson Syndrome and Common Children’s Medicines 2Health News:Personal Injury Law Firm Issues New Infographic Detailing a Potential Link Between Stevens Johnson Syndrome and Common Children’s Medicines 3Health News:American Career College Revs Up Community Support During Toyota Grand Prix of Long Beach 2Health News:Parents Underestimate Influence Over Teens' Substance Abuse: Survey 2Health News:Diagnostic coronary angiography: Functional flow reserve changes decisions in 25 percent of cases 2Health News:Youth with type 2 diabetes at much higher risk for heart, kidney disease 2
... CHAPEL HILL, N.C., May 27 As the ... companies are looking,for ways to up-sell and cross-sell ... the need for such practices, Best Practices LLC ... from less than 5% of their,service calls., ...
... NY/LOS ANGELES, CA: Stand Up To Cancer ... philanthropic dollars for accelerating ground-breaking research, launches today ... networks, entertainment industry executives, celebrities and prominent leaders ... CBS and NBC will donate one hour of ...
... TUCSON, Ariz., May 27 Medipacs, Inc., a ... is has secured an,initial financial investment of $1.65 ... Venture Partners and other investors in Tucson, San,Diego, ... Mark McWilliams comments: "We are very pleased with,the ...
... IMTEC Corporation proudly,introduces a newly redesigned version ... works in conjunction with IMTEC,s proprietary,FlashCT(R) software for ... scanner, Vision provides users with tools for viewing, ... may be in the form of,a raw scan ...
... in Melanoma , Mutations in the p14ARF tumor ... independent of the effect of the p16 gene. , ... on chromosome 9 that is frequently mutated in melanomas. ... p16 tumor suppressor gene occurs frequently in melanomas, it ...
... days off, poor-quality output, study finds , , TUESDAY, May ... hyperactivity disorder (ADHD) miss, on average, more than three ... new global reckoning of the problem. , Altogether, between ... ADHD, according to survey data from the World Health ...
Cached Medicine News:Health News:ABC, CBS, NBC announce historic collaboration to 'stand up to cancer' 2Health News:ABC, CBS, NBC announce historic collaboration to 'stand up to cancer' 3Health News:ABC, CBS, NBC announce historic collaboration to 'stand up to cancer' 4Health News:ABC, CBS, NBC announce historic collaboration to 'stand up to cancer' 5Health News:ABC, CBS, NBC announce historic collaboration to 'stand up to cancer' 6Health News:IMTEC Introduces New Vision Software 2Health News:Also in the May 27 JNCI 2Health News:Also in the May 27 JNCI 3Health News:Also in the May 27 JNCI 4Health News:Adults With ADHD Lose 3 Weeks Worth of Work Annually 2Health News:Adults With ADHD Lose 3 Weeks Worth of Work Annually 3
(Date:5/24/2013)... and BOSTON , May 24, 2013 /PRNewswire/ ... development company, is pleased to announce that it has engaged Mr ... the Company,s business development capabilities in Japan ... 15 years of experience in business development, licensing and alliance management ... Roche Pharma ( Japan ), Nippon Roche and Tanabe ...
(Date:5/23/2013)... DIEGO y PARÍS, 24 de mayo ... VOLC ), un destacado desarrollador y fabricante de ... mejorar la diagnosis y tratamiento de la enfermedad ... preliminares del ensayo ADVISE ( Ad enosine ... E valuation) II durante la sesión de ...
(Date:5/23/2013)... May 23, 2013  Haemonetics Corporation (NYSE: HAE ... CFO & EVP-Business Development, will present at The Deutsche Bank ... Boston, MA on May 29, 2013 at ... ) The public may access Mr. Lindop,s presentation ... About Haemonetics Haemonetics (NYSE: HAE ) ...
Breaking Medicine Technology:Heptares Augments Business Development Capabilities in Japan and Other Asian Territories 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
... 21, 2010 /PRNewswire-FirstCall/ – ERT (Nasdaq: ERES ... the pharmaceutical, biotechnology and medical device industries, today confirmed ... of Dr. Michael J. McKelvey, its President and CEO, ... currently ERT,s Chairman and Chief Scientific Officer, has also ...
... 21, 2010 PTC Therapeutics, Inc. announced today that ... trial of ataluren, an investigational new drug, in patients ... http://photos.prnewswire.com/prnh/20010919/PTCLOGO) The 48-week study is designed to ... with nmCF.  The trial has enrolled 238 patients at ...
Cached Medicine Technology:ERT Announces the Appointment of Joel Morganroth, MD as Interim CEO 2ERT Announces the Appointment of Joel Morganroth, MD as Interim CEO 3PTC Therapeutics Completes Enrollment of Phase 3 Trial of Ataluren in Patients with Cystic Fibrosis 2PTC Therapeutics Completes Enrollment of Phase 3 Trial of Ataluren in Patients with Cystic Fibrosis 3PTC Therapeutics Completes Enrollment of Phase 3 Trial of Ataluren in Patients with Cystic Fibrosis 4
... is designed to play a key ... research involves proteomics, cytomics or genomics. ... enhanced firmware, powerful Optima eXPert software ... L-XP delivers superior functionality, optimized user ...
... integrated chemistry system brings versatility in ... smaller laboratory. A model of innovation ... chemistry system features state-of-the-art Dimension testing ... environment, in a flexible. affordable, easy-to-use ...
The Express Plus clinical chemistry analyzer is a fully automated walk away system designed for maximum productivity, convenience and reliability....
... convenience make the RD/Hitachi 902 the ... workload laboratory. Compact, sample selective clinical ... 26 tests on board (including 3 ... tests per hour respectively up to ...
Medicine Products: